Shopping Cart 0
Cart Subtotal
USD 0

Alnylam Pharmaceuticals Inc (ALNY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Alnylam Pharma and Sanofi Enter into Agreement 14

Regeneron Pharma Enters into Agreement with Alnylam Pharma 15

Invitae Enters into Agreement with Alnylam Pharma 16

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17

BioXcel Enters into Agreement with Alnylam Pharma 18

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21

Licensing Agreements 22

Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25

Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26

Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28

Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29

Equity Offering 30

Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30

Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32

Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36

Alnylam Pharma Completes Public Offering Of Shares For USD 185 Million 37

Alnylam Pharma Completes Private Placement Of Shares For USD 185 Million 39

Alnylam Pharma Completes Public Offering Of Shares For USD 93 Million 41

Acquisition 43

Alnylam Pharma Acquires Sirna Therapeutics From Merck 43

Alnylam Pharmaceuticals Inc-Key Competitors 44

Alnylam Pharmaceuticals Inc-Key Employees 45

Alnylam Pharmaceuticals Inc-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Joint Venture 47

Recent Developments 48

Strategy And Business Planning 48

Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 48

Financial Announcements 50

Nov 07, 2018: Alnylam Pharmaceuticals reports third quarter 2018 financial results and highlights recent period activity 50

Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 53

May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 57

Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 60

Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 63

May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 65

Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 67

Corporate Communications 70

Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 70

Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 71

May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 72

Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 73

May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 74

Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 76

Legal and Regulatory 77

Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 77

Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 78

Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 79

Nov 03, 2017: Silence Therapeutics: Update on litigation matters 80

Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 81

Government and Public Interest 82

Oct 29, 2018: Hochschulmedizin Zurich and Alnylam host Innovative Medicine lecture on the discovery and clinical applications of RNA interference (RNAi) 82

Oct 24, 2018: Alnylam announces Advocacy for Impact Grants to inspire unique solutions that address unmet needs affecting the rare disease community 83

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 84

Product News 86

11/13/2017: European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis 86

11/03/2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 87

10/03/2018: Kaskela Law LLC Announces Investor Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of USD 100,000 to Contact the Firm 89

10/02/2018: Alnylam launches ONPATTRO (patisiran), the first-ever RNAi therapeutic, in Germany 90

09/24/2018: Alnylam Pharmaceuticals receives Priority Review in Canada for Patisiran, an investigational RNAi Therapeutic for the treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy 91

08/30/2018: Alnylam receives approval of ONPATTRO (patisiran) in Europe 92

08/20/2018: Veristat congratulates Alnylam on the FDA approval of ONPATTRO (patisiran) 94

08/14/2018: Onpattro is the first FDA-approved treatment for polyneuropathy 95

08/10/2018: Alnylam announces alignment on value-based agreements with leading health insurers and launches comprehensive patient support services for ONPATTRO (patisiran) 96

08/10/2018: Alnylam announces first-ever FDA approval of an RNAi therapeutic, ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults 98

08/03/2018: Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran 100

07/27/2018: Alnylam receives positive CHMP opinion for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy 101

06/08/2018: Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) 103

03/12/2018: Alnylam Receives Breakthrough Therapy Designation from FDA for Lumasiran 105

Product Approvals 106

Aug 07, 2018: Silence Therapeutics litigation: patisiran EU marketing authorisation imminent 106

Mar 26, 2018: Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 107

Feb 01, 2018: Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 108

Jan 25, 2018: Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 109

Dec 18, 2017: Sanofi and Alnylam Submit Marketing Authorization Application to the EMA for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 110

Dec 12, 2017: Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 111

Dec 11, 2017: Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis 112

Nov 16, 2017: Alnylam Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 113

Clinical Trials 114

Oct 08, 2018: Alnylam reports new positive Phase l/ll results from lumasiran trial 114

Sep 14, 2018: Alnylam announces publication in circulation of exploratory cardiac endpoint data from APOLLO phase 3 study of Patisiran 115

Jul 23, 2018: Alnylam presents new analyses of clinical results from APOLLO phase 3 study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting 117

Jul 04, 2018: Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine 119

Jun 15, 2018: Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology 121

May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery of RNAi Therapeutics 123

May 03, 2018: Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 124

Apr 24, 2018: Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting 125

Mar 28, 2018: Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis 127

Mar 14, 2018: Alnylam to Present Clinical Trial Data on Amyloidosis Drug Candidate ALN-TTRsc02 at the 16th International Symposium on Amyloidosis 129

Nov 20, 2017: U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy 130

Nov 02, 2017: Sanofi and Alnylam Present Positive Complete Results from APOLLO Phase 3 study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 132

Oct 20, 2017: Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors 135

Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 136

Sep 20, 2017: Arbutus' LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program 137

Sep 20, 2017: Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 138

Apr 26, 2017: Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 140

Appendix 142

Methodology 142

About GlobalData 142

Contact Us 142

Disclaimer 142


List Of Figure

List of Figures

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alnylam Pharma and Sanofi Enter into Agreement 14

Regeneron Pharma Enters into Agreement with Alnylam Pharma 15

Invitae Enters into Agreement with Alnylam Pharma 16

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17

BioXcel Enters into Agreement with Alnylam Pharma 18

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21

Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25

Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26

Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28

Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29

Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30

Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32

Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36

Alnylam Pharma Completes Public Offering Of Shares For USD 185 Million 37

Alnylam Pharma Completes Private Placement Of Shares For USD 185 Million 39

Alnylam Pharma Completes Public Offering Of Shares For USD 93 Million 41

Alnylam Pharma Acquires Sirna Therapeutics From Merck 43

Alnylam Pharmaceuticals Inc, Key Competitors 44

Alnylam Pharmaceuticals Inc, Key Employees 45

Alnylam Pharmaceuticals Inc, Subsidiaries 46

Alnylam Pharmaceuticals Inc, Joint Venture 47

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Alnylam Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Alnylam Pharma and Sanofi Enter into Agreement 14

Regeneron Pharma Enters into Agreement with Alnylam Pharma 15

Invitae Enters into Agreement with Alnylam Pharma 16

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17

BioXcel Enters into Agreement with Alnylam Pharma 18

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21

Licensing Agreements 22

Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25

Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26

Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28

Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29

Equity Offering 30

Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30

Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32

Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36

Alnylam Pharma Completes Public Offering Of Shares For USD 185 Million 37

Alnylam Pharma Completes Private Placement Of Shares For USD 185 Million 39

Alnylam Pharma Completes Public Offering Of Shares For USD 93 Million 41

Acquisition 43

Alnylam Pharma Acquires Sirna Therapeutics From Merck 43

Alnylam Pharmaceuticals Inc-Key Competitors 44

Alnylam Pharmaceuticals Inc-Key Employees 45

Alnylam Pharmaceuticals Inc-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Joint Venture 47

Recent Developments 48

Strategy And Business Planning 48

Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 48

Financial Announcements 50

Nov 07, 2018: Alnylam Pharmaceuticals reports third quarter 2018 financial results and highlights recent period activity 50

Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 53

May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 57

Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 60

Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 63

May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 65

Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 67

Corporate Communications 70

Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 70

Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 71

May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 72

Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 73

May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 74

Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 76

Legal and Regulatory 77

Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 77

Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 78

Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 79

Nov 03, 2017: Silence Therapeutics: Update on litigation matters 80

Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 81

Government and Public Interest 82

Oct 29, 2018: Hochschulmedizin Zurich and Alnylam host Innovative Medicine lecture on the discovery and clinical applications of RNA interference (RNAi) 82

Oct 24, 2018: Alnylam announces Advocacy for Impact Grants to inspire unique solutions that address unmet needs affecting the rare disease community 83

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 84

Product News 86

11/13/2017: European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis 86

11/03/2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 87

10/03/2018: Kaskela Law LLC Announces Investor Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of USD 100,000 to Contact the Firm 89

10/02/2018: Alnylam launches ONPATTRO (patisiran), the first-ever RNAi therapeutic, in Germany 90

09/24/2018: Alnylam Pharmaceuticals receives Priority Review in Canada for Patisiran, an investigational RNAi Therapeutic for the treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy 91

08/30/2018: Alnylam receives approval of ONPATTRO (patisiran) in Europe 92

08/20/2018: Veristat congratulates Alnylam on the FDA approval of ONPATTRO (patisiran) 94

08/14/2018: Onpattro is the first FDA-approved treatment for polyneuropathy 95

08/10/2018: Alnylam announces alignment on value-based agreements with leading health insurers and launches comprehensive patient support services for ONPATTRO (patisiran) 96

08/10/2018: Alnylam announces first-ever FDA approval of an RNAi therapeutic, ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults 98

08/03/2018: Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran 100

07/27/2018: Alnylam receives positive CHMP opinion for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy 101

06/08/2018: Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) 103

03/12/2018: Alnylam Receives Breakthrough Therapy Designation from FDA for Lumasiran 105

Product Approvals 106

Aug 07, 2018: Silence Therapeutics litigation: patisiran EU marketing authorisation imminent 106

Mar 26, 2018: Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 107

Feb 01, 2018: Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 108

Jan 25, 2018: Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 109

Dec 18, 2017: Sanofi and Alnylam Submit Marketing Authorization Application to the EMA for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 110

Dec 12, 2017: Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 111

Dec 11, 2017: Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis 112

Nov 16, 2017: Alnylam Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 113

Clinical Trials 114

Oct 08, 2018: Alnylam reports new positive Phase l/ll results from lumasiran trial 114

Sep 14, 2018: Alnylam announces publication in circulation of exploratory cardiac endpoint data from APOLLO phase 3 study of Patisiran 115

Jul 23, 2018: Alnylam presents new analyses of clinical results from APOLLO phase 3 study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting 117

Jul 04, 2018: Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine 119

Jun 15, 2018: Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology 121

May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery of RNAi Therapeutics 123

May 03, 2018: Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 124

Apr 24, 2018: Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting 125

Mar 28, 2018: Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis 127

Mar 14, 2018: Alnylam to Present Clinical Trial Data on Amyloidosis Drug Candidate ALN-TTRsc02 at the 16th International Symposium on Amyloidosis 129

Nov 20, 2017: U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy 130

Nov 02, 2017: Sanofi and Alnylam Present Positive Complete Results from APOLLO Phase 3 study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 132

Oct 20, 2017: Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors 135

Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 136

Sep 20, 2017: Arbutus' LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program 137

Sep 20, 2017: Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 138

Apr 26, 2017: Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 140

Appendix 142

Methodology 142

About GlobalData 142

Contact Us 142

Disclaimer 142


List Of Figure

List of Figures

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alnylam Pharma and Sanofi Enter into Agreement 14

Regeneron Pharma Enters into Agreement with Alnylam Pharma 15

Invitae Enters into Agreement with Alnylam Pharma 16

Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17

BioXcel Enters into Agreement with Alnylam Pharma 18

Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19

Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21

Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22

Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25

Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26

Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27

Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28

Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29

Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30

Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32

Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36

Alnylam Pharma Completes Public Offering Of Shares For USD 185 Million 37

Alnylam Pharma Completes Private Placement Of Shares For USD 185 Million 39

Alnylam Pharma Completes Public Offering Of Shares For USD 93 Million 41

Alnylam Pharma Acquires Sirna Therapeutics From Merck 43

Alnylam Pharmaceuticals Inc, Key Competitors 44

Alnylam Pharmaceuticals Inc, Key Employees 45

Alnylam Pharmaceuticals Inc, Subsidiaries 46

Alnylam Pharmaceuticals Inc, Joint Venture 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Alnylam Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.